A bridging study of LU 25-109 in patients with probable Alzheimer's disease (Q34458776)

2 August 2017

title

A bridging study of LU 25-109 in patients with probable Alzheimer's disease (English)

1 reference

2 August 2017

0 references

Sramek JJ

1

1 reference

2 August 2017

Forrest M

2

1 reference

2 August 2017

Mengel H

3

1 reference

2 August 2017

Jhee SS

4

1 reference

2 August 2017

Hourani J

5

1 reference

2 August 2017

Cutler NR

6

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 1998

1 reference

2 August 2017

1 reference

2 August 2017

volume

62

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

195-202

1 reference

Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Cholinergic receptors in aging and Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Safety and tolerability of CI-979 in patients with Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

In vivo consequences of M1-receptor activation by talsaclidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2901087-4

10.1016/S0024-3205(97)01087-4

7 January 2021

Identifiers

DOI

1 reference

release_bklvo3cjybhfdh75j5qwr5utz4

2 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bklvo3cjybhfdh75j5qwr5utz4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference